Anatara Lifesciences Ltd (ANR.AX) Investor Presentation
This presentation had been largely prepared prior to last week's announcement that animal health company, Zoetis had made a portfolio decision not to continue with the pursuit of Anatara's lead animal health asset, Detach(R). To that end, while a new slide has been incorporated to reflect the current state of affairs with Detach(R), this presentation does not reflect the new commercialisation strategy for Detach(R), which Anatara's Board and Management team is closely reviewing over the coming weeks.
CEO, Steve Lydeamore commented, "We have been working hard this year to communicate with investors as transparently as possible regarding our progress. Continuing with our planned presentations in Perth and the Gold Coast this month is in keeping with our desire to communicate openly.
While the Board does not have all the answers regarding the future of the Detach(R) program at this stage, we are focused on determining the next steps in a timely manner and will communicate those as soon as practical in the coming weeks. In the meantime, we look forward to engaging with investors to discuss what we currently know and discuss the work we're doing in the area of human gastrointestinal health through our dietary supplement program."
Any shareholders with questions regarding Anatara's recent announcements or the attached investor presentation are invited to contact the company using the contact info below. Those investors wishing to attend the Gold Coast Investment Showcase are invited to register for complementary attendance via this link: http://www.abnnewswire.net/lnk/MQ2A70M6
To view the investor presentation, please visit:
About Anatara Lifesciences Ltd:
Anatara Lifesciences (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatara is a life sciences company with expertise in developing products for animal and human health. Anatara is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders. For more information, please visit www.anataralifesciences.com.
Anatara Lifesciences Ltd
Investor inquiries Mr Steven Lydeamore Chief Executive Officer Anatara Lifesciences Ltd T: +61-438-027-172 E: email@example.com Media inquiries Jane Lowe Managing Director, IR Department T: +61-411-117-774 E: firstname.lastname@example.org
ABN Newswire is a business newswire and press release distribution service for listed companies on stock exchanges globally. ABN Newswire distributes company announcements to the professional platforms, finance portals and syndicates important corporate news to a wide variety of news aggregators and financial news systems.